PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|September 30, 2015
Clariant to Showcase Pharma Polymers and Packaging Solutions at CPhI Worldwide 2015
Exhibits include controlled atmosphere packaging for protection against moisture and oxygen, as well as specialty polymers and active ingredients for healthcare applications, among others.
Advertisement
Clariant announced that it will be at CPhI Worldwide 2015 to showcase its product offerings for the pharmaceutical market. Three business groups from the company will exhibit in Hall 7, Booth 7F28.
- Business Unit Industrial & Consumer Specialties will present innovative, sustainable and trend-based products to support the changing needs of the pharmaceutical market. High-purity ingredients include Polyglykol universally applicable pharmaceutical polymers, and a complete range of Macrogols with various molecular weights, all of them supported by CEP certification and DMF.
- Clariant Healthcare Packaging manufactures controlled atmosphere packaging that helps to protect healthcare products from humidity and oxygen. Its portfolio includes industry-leading desiccant canisters and packets; tubes and desiccant stoppers; Tubairless, an innovative airless packaging system for protecting and dispensing sensitive pharmaceutical semi-solids and creams; EQ-Can and EQ-Pak humidity regulators; and more.
- Clariant Healthcare Polymer Solutions will featuring the MEVOPUR and the REMAFIN-EP brands of color and performance master batches and compounds developed specifically for the medical device and pharmaceutical packaging sector, including new UV-blocking protection for transparent packaging, improved resistance to e-beam, gamma, X-ray sterilization, and new anti-static and anti-blocking functionality for pharmaceutical packaging films. The REMAFIN-EP range of white master batches for pharmaceutical packaging has been extended with increased regulatory support with test documentation for USP661.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement